The dynamics of Rett Syndrome market is anticipated to change in the upcoming years owing to the improvement in the research and development

Rett Syndrome Market

The Rett Syndrome Market report from DelveInsight provides an in-depth understanding of the Rett Syndrome, historical and forecasted epidemiology, as well as Rett Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the Important Findings from the Rett Syndrome Market Report

• According to research by M. Itoh et al. titled “Epidemiological study of Japanese Rett syndrome,” the prevalence of Rett Syndrome in Japan is 0.90 per 10,000 females.

• According to a research undertaken by the European Union’s Health Programme, the estimated prevalence of Rett Syndrome in Europe is 10.0 per 100,000, with a birth prevalence of 5.0 per 100,000.

• According to the National Congenital Anomaly and Rare Diseases Registration Service (NCARDRS), Rett Syndrome affects roughly one out of every 12,000 females born each year globally, and it is rarely found in men.

• According to the National Organization for Rare Disorders, Rett syndrome affects one out of every 10,000 girls in the United States by the age of 12.

• NNZ-2566 (Trofinetide) (Neuren Pharmaceuticals/Acadia Pharmaceuticals), GWP42003-P (Epidiolex) (GW Research), ANAVEX 2-73 (blarcamesine) (Anavex Life Sciences), Dojolvi (Ultragenyx Pharmaceutical), are some of the most anticipated emerging therapies in the Rett Syndrome market.

• Neuren Pharmaceuticals, Acadia Pharmaceuticals, GW Research, Anavex Life Sciences, Ultragenyx Pharmaceutical are among the companies which are proactively working in the Rett Syndrome market.

Want to know more? Request sample @Rett Syndrome Market Insights

The Rett Syndrome market report covers current treatment methods, developing therapies, individual therapy market share, and present and predicted Rett Syndrome market size from 2018 to 2030, segmented into seven major markets.

Rett Syndrome: Disease Overview

Rett Syndrome is a rare neurodevelopmental disorder that affects mostly females but can sometimes impact boys. It is first identified in infancy. It is caused by mutations in the MECP2 gene on the X-chromosome. On the MECP2 gene, there are over 200 distinct mutations. The majority of these mutations are concentrated in eight distinct “hot spots.” Autism, cerebral palsy, and global developmental delay are all common misdiagnoses for Rett syndrome. It affects people of all ethnic and racial backgrounds.

Rett Syndrome Epidemiology Segmentation

• Rett Syndrome Prevalent Cases

• Rett Syndrome Gender-Specific Prevalent Cases

• Rett Syndrome Age-Specific Prevalent Cases

• Rett Syndrome Diagnosed and Treatable Cases

Rett Syndrome Treatment Landscape

There is currently no therapy available for the treatment of Rett syndrome on the market. Rett syndrome treatment is symptomatic, meaning it focuses on managing symptoms, which necessitates a multidisciplinary approach. The most common types of treatment for Rett Syndrome include:

• Speech-language therapy

• Physical Therapy

• Off-label Medications (bromocriptine, carbidopa-levodopa, levocarnitine, etc.)

• Hydrotherapy

• Diet Management

• Occupational Therapy

• Antidepressants (trazodone)

Rett Syndrome Market

The total market size for Rett Syndrome will comprise both upcoming therapies such as NNZ-2566 (Trofinetide) (Neuren Pharmaceuticals/Acadia Pharmaceuticals), GWP42003-P (Epidiolex) (GW Research), ANAVEX 2-73 (blarcamesine) (Anavex Life Sciences), Dojolvi (Ultragenyx Pharmaceutical) and current treatment regimens, which will include many off-label medicines used in the seven major markets.

Learn more about Rett Syndrome @ Rett Syndrome Market Outlook and Treatment Landscape

Rett Syndrome Pipeline Therapies and Key Companies

• NNZ-2566 (Trofinetide): Neuren Pharmaceuticals/Acadia Pharmaceuticals

• GWP42003-P (Epidiolex): GW Research

• ANAVEX 2-73 (blarcamesine): Anavex Life Sciences

• Dojolvi: Ultragenyx Pharmaceutical

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2018-30

Rett Syndrome Key Companies: Neuren Pharmaceuticals, Acadia Pharmaceuticals, GW Research, Anavex Life Sciences, Ultragenyx Pharmaceutical, among others. 

Rett Syndrome Key Pipeline Therapies: NNZ-2566 (Trofinetide) (Neuren Pharmaceuticals/Acadia Pharmaceuticals), GWP42003-P (Epidiolex) (GW Research), ANAVEX 2-73 (blarcamesine) (Anavex Life Sciences), Dojolvi (Ultragenyx Pharmaceutical), and others.

Rett Syndrome Market Segmentation: By Geography, By Rett Syndrome therapies

Analysis: Comparative and conjoint analysis of Rett Syndrome emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

Alagille Syndrome Market

Get comprehensive historical and forecast analysis of Alagille Syndrome Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Mirum Pharmaceuticals, Albireo, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/